Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02959489 · ClinicalTrials.gov registry record · NA
Risk Evaluation and Education for Alzheimer's Disease - the Study of Communicating Amyloid Neuroimaging (REVEAL-SCAN)
A NA study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- NA
- Development phase
- 315
- Enrollment target
NCT02959489: Completed NA study, sponsored by Brigham and Women's Hospital.
NCT02959489 is a NA study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 315 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02959489, a NA study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 315 participants
- Enrollment target
Study Summary
This study is intended to examine the impact of learning amyloid brain imaging results among asymptomatic older adults, and how to safely communicate these results and educate on the risk of developing Alzheimer's disease.
Primary Outcome
Assessed via the A4 Study's Preclinical Alzheimer Cognitive Composite (ADCS-PACC) battery, which combines tests that measure episodic memory, timed executive function, and global cognition.
Interventions
- BEHAVIORAL Alzheimer's Disease Risk Disclosure
- BEHAVIORAL Amyloid Brain Imaging and Alzheimer's Disease Risk Disclosure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 315 participants |
| Start Date | 2016-11 |
| Est. Completion | 2021-04-29 |
| Phase | NA |
What the finished NCT02959489 record still lists
NCT02959489 is an interventional study that assigns participants to a tested intervention. The registered 315 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (78% lower).
The record links to 0 conditions, and to 2 interventions - of which Alzheimer's Disease Risk Disclosure is the first listed.
NCT02959489 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02959489 about?
NCT02959489 is a clinical study titled "Risk Evaluation and Education for Alzheimer's Disease - the Study of Communicating Amyloid Neuroimaging (REVEAL-SCAN)". This study is intended to examine the impact of learning amyloid brain imaging results among asymptomatic older adults, and how to safely communicate these results and educate on the risk of developing Alzheimer's disease.
What is the current status of trial NCT02959489?
This trial is currently completed. It is a NA study. The enrollment target is 315 participants. The study started on 2016-11. Estimated completion is 2021-04-29.
What interventions are being tested in trial NCT02959489?
The interventions under investigation include: Alzheimer's Disease Risk Disclosure (BEHAVIORAL), Amyloid Brain Imaging and Alzheimer's Disease Risk Disclosure (BEHAVIORAL).
Who is sponsoring clinical trial NCT02959489?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02959489's enrollment target sits among peer trials
315 323rd of 2000 higher than 1,678 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04812366 · 315 participants · Phase 2
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
- NCT05101460 · 315 participants
An All Comers Registry For Normothermic Ex Vivo Lung Perfusion (EVLP) as Assessment of Donor Lungs for Transplant
- NCT05897320 · 315 participants · Phase 3
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
- NCT06439082 · 315 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia